# Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

> **NCT03168438** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 6 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Letetresgene autoleucel
- **DRUG:** Letetresgene autoleucel with pembrolizumab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03168438
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-18
- **Primary completion:** 2020-07-13
- **Final completion:** 2020-11-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was terminated following an internal review of the company's research and development portfolio
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168438, "Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03168438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*